comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO.: 7 and a light chain variable region having the amino acid sequence of SEQ ID NO.: 9. In certain examples, the anti-IL13 antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO.: 10 and a light chain having the amino acid sequence of SEQ ID NO.: 14. In certain examples, the amount of hamster PLBL2 in the composition is quantified using an immunoassay or a mass spectrometry assay. In certain examples, the immunoassay is a total Chinese hamster ovary protein ELISA or a hamster PLBL2 ELISA. In certain examples, the mass spectrometry assay is LC-MS/MS.

[0023] In another ~~aspect~~example, anti-IL13 monoclonal antibody preparations isolated and purified from CHO cells by a process comprising a hydrophobic interaction chromatography (HIC) step are provided. In certain examples, the purified preparation comprises the anti-IL13 antibody and a residual amount of hamster PLBL2. In certain examples, the amount of hamster PLBL2 is less than 20 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 15 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 10 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 8 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 5 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 3 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 2 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 1 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 0.5 ng/mg. In certain examples, the amount of hamster PLBL2 is between 0.5 ng/mg and 20 ng/mg, or between 0.5 ng/mg and 15 ng/mg, or between 0.5 ng/mg and 10 ng/mg, or between 0.5 ng/mg and 8 ng/mg, or between 0.5 ng/mg and 5 ng/mg, or between 0.5 ng/mg and 3 ng/mg, or between 0.5. ng/mg and 2 ng/mg, or between 0.5 ng/mg and 1 ng/mg, or between the limit of assay quantitation (LOQ) and 1 ng/mg. In certain examples, the HIC step comprises PHENYL SEPHAROSE™ 6 Fast Flow (High Sub) resin. In certain examples, the HIC step comprises operating a resin-containing column in flow-through mode. In certain examples, the HIC step comprises an equilibration buffer and a wash buffer, wherein each of the equilibration buffer and the wash buffer comprise 50 mM sodium acetate pH 5.0. In certain examples, the flow-through is monitored by absorbance at 280 nanometers and the flow-through is collected between 0.5 OD to 1.5 OD. In certain examples, the flow-through is collected for a maximum of 8 column volumes. In certain examples, the process further comprises an affinity chromatography step. In certain examples, the affinity chromatography is protein A chromatography. In certain examples, the process further comprises an ion exchange chromatography step. In certain examples, the ion

disclosure refers to a method of purifying a recombinant polypeptide produced in Chinese hamster ovary (CHO) host cells and having phospholipase B-like 2 (PLBL2) levels greater than 100 ng/mg, wherein the method comprises performing a hydrophobic interaction chromatography (HIC) step and provides a purified preparation comprising the recombinant polypeptide and a residual amount of ~~hamster phospholipase B-like 2 (~~PLBL2~~)~~, wherein the residual amount of hamster PLBL2 is less than 20 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 20 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 15 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 10 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 8 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 5 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 3 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 2 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 1 ng/mg. In certain examples, the amount of hamster PLBL2 is less than 0.5 ng/mg. In certain examples, the amount of hamster PLBL2 is between 0.5 ng/mg and 20 ng/mg, or between 0.5 ng/mg and 15 ng/mg, or between 0.5 ng/mg and 10 ng/mg, or between 0.5 ng/mg and 8 ng/mg, or between 0.5 ng/mg and 5 ng/mg, or between 0.5 ng/mg and 3 ng/mg, or between 0.5. ng/mg and 2 ng/mg, or between 0.5 ng/mg and 1 ng/mg, or between the limit of assay quantitation (LOQ) and 1 ng/mg. In certain examples, the recombinant polypeptide is selected from a growth factor, a cytokine, an antibody, an antibody fragment, and an immunoadhesin. In certain examples, the recombinant polypeptide is an antibody. In certain examples, the antibody is a humanized monoclonal antibody. In certain examples, the antibody is IgG1, or IgG2, or IgG3, or IgG4. In certain examples, the antibody is IgG1. In certain examples, the antibody is IgG2. In certain examples, the antibody is IgG3. In certain examples, the antibody is IgG4. In certain examples, the methods comprise a hydrophobic interaction chromatography (HIC) step. In certain examples, the HIC step comprises PHENYL SEPHAROSE™ 6 Fast Flow (High Sub) resin.

[0026] In certain examples of the above purification methods, the purified antibody is anti-IL13. In certain examples, the antibody is lebrikizumab. In certain examples, the HIC step comprises operating a resin-containing column in flow-through mode. In certain examples, the HIC step comprises an equilibration buffer and a wash buffer, wherein each of the equilibration buffer and the wash buffer comprise 50 mM sodium acetate pH 5.0. In certain examples, the flow-through is monitored by absorbance at 280 nanometers and the flow-through is collected between 0.5 OD to 1.5 OD. In certain examples, the flow-through is collected for a maximum of 8 column volumes. In certain examples, the methods further comprise an affinity chromatography step. In certain examples, the affinity chromatography is protein A chromatography. In certain examples, the methods further comprise an ion exchange chromatography step. In certain examples, the ion

WHAT IS CLAIMED IS:

1. A method of purifying a recombinant polypeptide produced in Chinese hamster ovary (CHO) host cells and having phospholipase B-like 2 (PLBL2) levels greater than 100 ng/mg, wherein the method comprises performing a hydrophobic interaction chromatography (HIC) step and provides a purified preparation comprising the recombinant polypeptide and a residual amount of hamster ~~phospholipase B-like 2 (~~PLBL2~~)~~, wherein the residual amount of hamster PLBL2 is less than 20 ng/mg.

~~2. The method of claim 1, wherein the recombinant polypeptide produced in CHO host cells has PLBL2 levels great than 100 ng/mg.~~

~~3.~~2. The method of claim 1 ~~or claim 2~~, wherein the residual amount of hamster PLBL2 is ~~less than 20 ng/mg, or~~ less than 15 ng/mg, or less than 10 ng/mg, or less than 8 ng/mg, or less than 5 ng/mg, or less than 3 ng/mg, or less than 2 ng/mg, or less than 1 ng/mg, or less than 0.5 ng/mg.

~~4. The method of claim 3, wherein the residual amount of hamster PLBL2 is less than 20 ng/mg.~~

~~5. The method of any one of the preceding claims comprising performing a hydrophobic interaction chromatography (HIC) step.~~

~~6.~~3. The method of claim ~~5~~ 1 or claim 2, wherein the HIC step comprises PHENYL SEPHAROSE™ 6 Fast Flow ~~(High Sub)~~ high substitution resin.

~~7.~~4. The method of claim ~~6~~3, wherein the HIC step comprises operating a PHENYL SEPHAROSE™ 6 Fast Flow ~~(High Sub)~~high substitution resin-containing column in flow-through mode.

~~8.~~5. The method of any one of the preceding claims, wherein the recombinant polypeptide is selected from a growth factor, a cytokine, an antibody, an antigen-binding antibody fragment, and an immunoadhesin.

~~9. The method of claim 8, wherein the antibody is an antigen-binding antibody fragment.~~

~~10.~~6. The method of claim ~~8~~5, wherein the recombinant polypeptide is an antibody.

~~11.~~7. The method of claim ~~9~~6, wherein the antibody is a humanized monoclonal antibody.

~~12.~~8. The method of claim ~~10~~6, wherein the antibody is IgG1, or IgG2, or IgG3, or IgG4.

~~13.~~9. The method of claim ~~11~~8, wherein the antibody is IgG4.

~~14.~~10. The method of claim ~~5~~1 or claim 2, wherein the HIC step comprises operating a resin-containing column in flow-through mode and an equilibration buffer and a wash buffer, wherein each of the equilibration buffer and the wash buffer comprise 50 mM sodium acetate pH 5.0.

~~15.~~11. The method of claim ~~14~~10, wherein the flow-through is monitored by absorbance at 280 nanometers and the flow-through is collected between 0.5 OD to 1.5 OD.

~~16.~~12. The method of claim ~~14~~ 10 or claim ~~15~~11, wherein the flow-through is collected for a maximum of 8 column volumes.

~~17.~~13. The method of any one of claims claim ~~14~~ 10 to ~~16~~12, further comprising an affinity chromatography step.

~~18.~~14. The method of claim ~~17~~13, wherein the affinity chromatography is protein A chromatography.

~~19.~~15. The method of claim ~~14~~10, further comprising an ion exchange chromatography step.

~~20.~~16. The method of claim ~~19~~15, wherein the ion exchange chromatography is anion exchange chromatography.

~~21.~~17. The method of claim ~~14~~ 10 comprising a first Protein A affinity chromatography step and a second anion exchange chromatography step prior to the hydrophobic interaction chromatography (HIC) step.

~~22.~~18. The method of claim ~~21~~17, wherein the affinity chromatography step comprises MABSELECT SURE™ resin, the anion exchange chromatography step comprises Q SEPHAROSE™ Fast Flow, and the HIC step comprises PHENYL SEPHAROSE™ 6 Fast Flow ~~(high sub)~~high substitution resin.

~~23.~~19. The method of claim ~~22~~18, wherein:

the affinity chromatography step comprises operating a MABSELECT SURE™ resin-containing column in bind-elute mode;

the anion exchange chromatography step comprises operating a Q SEPHAROSE™ Fast Flow resin-containing column in bind-elute mode, and

the HIC step comprises operating a PHENYL SEPHAROSE™ 6 Fast Flow high substitution~~(High Sub)~~ resin-containing column in flow-through mode.

~~24.~~20. The method of claim ~~5~~1 or claim 2, wherein the HIC step comprises operating a resin-containing column in flow-through mode and an equilibration buffer and a wash buffer, wherein each of the equilibration buffer and the wash buffer comprise 150 mM sodium acetate pH 5.0.

~~25.~~21. The method of claim ~~24~~20, wherein the flow-through is monitored by absorbance at 280 nanometers and the flow-through is collected beginning at 0.5 OD and for 10 column volumes.

~~26.~~22. The method of claim ~~24~~ 20 or claim ~~25~~21, further comprising an affinity chromatography step.

~~27.~~23. The method of claim ~~26~~22, wherein the affinity chromatography is protein A chromatography.

~~28.~~24. The method of claim ~~24~~20, further comprising a mixed mode chromatography step.

~~29.~~25. The method of claim ~~24~~ 20 comprising a first Protein A affinity chromatography step and a second mixed mode chromatography step prior to the hydrophobic interaction chromatography (HIC) step.

~~30.~~26. The method of claim ~~29~~25, wherein the affinity chromatography step comprises MABSELECT SURE™ resin, the mixed mode chromatography step comprises CAPTO™ Adhere, and the HIC step comprises PHENYL SEPHAROSE™ 6 Fast Flow high substitution resin~~(high sub)~~.

~~31.~~27. The method of claim ~~30~~26, wherein:

the affinity chromatography step comprises operating a MABSELECT SURE™ resin-containing column in bind-elute mode;

the mixed mode chromatography step comprises operating a CAPTO™ Adhere resin-containing column in flow-through mode, and

the HIC step comprises operating a PHENYL SEPHAROSE™ 6 Fast Flow high substitution~~(High Sub)~~ resin-containing column in flow-through mode.

~~32.~~28. The method of claim 1, wherein the amount of hamster PLBL2 is quantified using an immunoassay or a mass spectrometry assay.

~~33.~~29. The method of claim ~~32~~28, wherein the immunoassay is a total Chinese hamster ovary protein ELISA or a hamster PLBL2 ELISA.

~~34.~~30. The method of claim ~~32~~28, wherein the mass spectrometry assay is LC-MS/MS.